Federico Monczor

Prof. Dr. Federico Monczor


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
FMFederico Monczor
Federico Monczor
NFNatalia Fernandez
Natalia Fernandez
![Figure][1] H1 and H2 histamine receptor antagonists, although developed many decades ago, are still effective for the treatment of allergic and gastric acid–related conditions. This article focuses on novel aspects of the pharmacology and molecular mechanisms of histamine receptors that should be contemplated for optimizing current therapies, repositioning histaminergic ligands for new therapeutic uses, or even including agonists of the histaminergic system in the treatment of different pathologies such as leukemia or neurodegenerative disorders. In recent years, new signaling phenomena related to H1 and H2 receptors have been described that make them suitable for novel therapeutic approaches. Crosstalk between histamine receptors and other membrane or nuclear receptors can be envisaged as a way to modulate other signaling pathways and to potentiate the efficacy of drugs acting on different receptors. Likewise, biased signaling at histamine receptors seems to be a pharmacological feature that can be exploited to investigate nontraditional therapeutic uses for H1 and H2 biased agonists in malignancies such as acute myeloid leukemia and to avoid undesired side effects when used in standard treatments. It is hoped that the molecular mechanisms discussed in this review contribute to a better understanding of the different aspects involved in histamine receptor pharmacology, which in turn will contribute to increased drug efficacy, avoidance of adverse effects, or repositioning of histaminergic ligands. [1]: pending:yes

1 May 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MTMaria Rosario Tubio
Maria Rosario Tubio
NFNatalia Fernandez
Natalia Fernandez
CFCarlos Patricio Fitzsimons
Carlos Patricio Fitzsimons
SCSabrina Copsel
Sabrina Copsel
SSSergio Santiago
Sergio Santiago
FMFederico Monczor
Federico Monczor
The idea of G protein-coupled receptors (GPCRs) coupling to G protein solely in their active form was abolished when it was found that certain ligands induce a G protein-coupled but inactive receptor form. This receptor form interferes with signaling of other receptors by sequestering G protein. However, the spontaneous existence of this receptor species has never been established. The aim of the present work was to evaluate the existence of the spontaneous conformation of the receptor inactively coupled to G protein able to interfere with the response of other GPCRs. According to the law of mass action, receptor overexpression should lead to increased amounts of all spontaneously occurring species. Based on this, we generated Chinese hamster ovary (CHO-K1)-derived cell lines expressing various amounts of the human histamine H2 receptor. In these systems, the signaling of other endogenously and transiently expressed GPCRs was attenuated proportionally to human H2 receptor expression levels. G protein transfection specifically reverted this attenuation, strongly suggesting hijacking of the G protein from a common pool. Similar attenuation effects were observed when the beta(2)- adrenergic receptor was overexpressed, suggesting that this is a more general phenomenon. Moreover, in human mammary MDA-MB-231 cells, a consistent increase in the response of other GPCRs was observed when endogenous expression of beta(2)-adrenergic receptor was knocked down using specific small interfering RNAs. Our findings show that GPCRs may interact with the signaling of other receptors by modulating the availability of the G protein and suggest the existence of GPCR spontaneous coupling to G proteins in an inactive form.

1 September 2013 in European Journal of Pharmacology
Verified
Journal Article
Open access
FMFederico Monczor
Federico Monczor
NFNatalia Fernandez
Natalia Fernandez
CFCarlos P. Fitzsimons
Carlos P. Fitzsimons
CSCarina Shayo
Carina Shayo
CDCarlos Davio
Carlos Davio
The accurate characterization of the molecular mechanisms involved in the action of receptor ligands is important for their appropriate therapeutic use and safety. It is well established that ligands acting at the histamine system currently used in the clinic exert their actions by specifically antagonizing G-protein coupled H1 and H2 receptors. However, most of these ligands, assumed to be neutral antagonists, behave as inverse agonists displaying negative efficacy in experimental systems. This suggests that their therapeutic actions may involve not only receptor blockade, but also the decrease of spontaneous receptor activity. The mechanisms whereby inverse agonists achieve negative efficacy are diverse. Theoretical models predict at least three possible mechanisms, all of which are supported by experimental observations. Depending on the mechanism of action engaged, the inverse agonist could interfere specifically with signaling events triggered by unrelated receptors. This possibility opens up new venues to explain the therapeutic actions of inverse agonists of the histamine receptor and perhaps new therapeutic applications.

4 December 2015 in Scientific Reports
Verified
Journal Article
Open access
CZCarlos Daniel Zappia
Carlos Daniel Zappia
GGGina Granja-Galeano
Gina Granja-Galeano
NFNatalia Fernández
Natalia Fernández
CSCarina Shayo
Carina Shayo
CDCarlos Davio
Carlos Davio
FMFederico Monczor
Federico Monczor
Histamine H1 receptor (H1R) antagonists and glucocorticoid receptor (GR) agonists are used to treat inflammatory conditions such as allergic rhinitis, atopic dermatitis and asthma. Consistent with the high morbidity levels of such inflammatory conditions, these receptors are the targets of a vast number of approved drugs, and in many situations their ligands are co-administered. However, this drug association has no clear rationale and has arisen from clinical practice. We hypothesized that H1R signaling could affect GR-mediated activity, impacting on its transcriptional outcome. Indeed, our results show a dual regulation of GR activity by the H1R: a potentiation mediated by G-protein βγ subunits and a parallel inhibitory effect mediated by Gαq-PLC pathway. Activation of the H1R by its full agonists resulted in a composite potentiating effect. Intriguingly, inactivation of the Gαq-PLC pathway by H1R inverse agonists resulted also in a potentiation of GR activity. Moreover, histamine and clinically relevant antihistamines synergized with the GR agonist dexamethasone to induce gene transactivation and transrepression in a gene-specific manner. Our work provides a delineation of molecular mechanisms underlying the widespread clinical association of antihistamines and GR agonists, which may contribute to future dosage optimization and reduction of well-described side effects associated with glucocorticoid administration.

3 February 2006 in Biochemical Pharmacology
Verified
Journal Article
Closed access
FMFederico Monczor
Federico Monczor
NFNatalia Fernandez
Natalia Fernandez
EREugenia Riveiro
Eugenia Riveiro
AMAlejandro Mladovan
Alejandro Mladovan
ABAlberto Baldi
Alberto Baldi
CDCarlos Davio
Carlos Davio

1 April 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
VBValeria Burghi
Valeria Burghi
EEEmiliana B. Echeverría
Emiliana B. Echeverría
CZCarlos D. Zappia
Carlos D. Zappia
ANAntonela Díaz Nebreda
Antonela Díaz Nebreda
SRSonia Ripoll
Sonia Ripoll
NFNatalia C. Fernández
Natalia C. Fernández